Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report report published on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of NASDAQ BLPH opened at $0.05 on Monday. The firm’s 50 day moving average price is $0.05 and its 200-day moving average price is $0.06. The company has a market cap of $661,805.30, a PE ratio of -0.06 and a beta of 0.67. Bellerophon Therapeutics has a 52-week low of $0.03 and a 52-week high of $11.15.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.